The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
Crossref DOI link: https://doi.org/10.1007/s13300-016-0206-7
Published Online: 2016-10-27
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gordon, Jason
McEwan, Phil
Hurst, Michael
Puelles, Jorge
Funding for this research was provided by:
Takeda Development Centre Europe
Text and Data Mining valid from 2016-10-27
Article History
Received: 23 August 2016
First Online: 27 October 2016